

19 May 2005



Mimotopes Update.

PharmAust Limited (ASX: PAA) is pleased to provide the following update on wholly owned subsidiary, Mimotopes Pty Ltd. Acquired by PAA in March 2005, Mimotopes provides discovery chemistry products and services to the global pharmaceutical and biotechnology industries mainly in the Peptide area.

Strong Initial Sales

Since becoming a member of the PharmAust group of companies Mimotopes has achieved strong initial sales.

Mimotopes has also produced invoices totalling more than \$720,000 in its first 10 weeks of operation.

PharmAust subsidiary, Mimotopes initially received an order to supply \$830,000 worth of its patented SynPhase™ components to a large overseas pharmaceutical group aligned with Novartis and approx. \$ 350,000 of this order has been invoiced so far. Mimotopes is working hard to complete shipments for the order, which is expected to conclude in June 2005.

PharmAust Ltd CEO, Mr John Moursounidis said: "Since PharmAust acquired the Mimotopes business in March, we've been very pleased with the strong level of new orders arriving and the loyalty of Mimotopes customers."

"It's been a wonderful reflection of our belief in the Company, its people, its products and its future and we are looking forward to seeing the impact Mimotopes has on the next set of quarterly results of the PharmAust group" he said.

New Managing Director

Commencing July 1, PAA Non Executive Chairman and former Director of Research & Development at Murdoch University, Dr Paul D'Sylva will take on the role of Managing Director at Mimotopes.

Dr D'Sylva, who played a key role in the acquisition of Mimotopes, will focus on further developing Mimotopes' core business of peptide synthesis by consolidating the existing client base and expanding into new markets.

Dr D'Sylva said: "PAA considers Mimotopes an ideal opportunity to expand and augment its drug and chemistry discovery business and the Board will look to exploit the synergy between Epichem and Mimotopes by combining the expertise of staff and management in both businesses.

“I am thrilled at this opportunity to lead Mimotopes through this exciting phase of its development as part of the PharmAust group of companies.”

The Mimotopes Business Model

Acquired by PAA in March 2005, wholly owned subsidiary Mimotopes provides discovery chemistry products and services to the global pharmaceutical and biotechnology industries.

Its cornerstone technology is the patented SynPhase™ chemistry platform, which allows for the fast production of large numbers of drug compounds. SynPhase™ has major applications in areas such as immunology and drug discovery.

Based in Victoria, Mimotopes comprises three business units:

Discovery Chemistry: Provides tailored chemistry service solutions for advanced drug discovery programs. This is similar work currently being undertaken by another PharmAust subsidiary Epichem but concentrating mainly on Peptides.

SynPhase: Offers a range of innovative products for combinatorial and solid-phase chemistry using the Company's patented technology platform, SynPhase™.

Peptides: Creates synthesised peptides for a broad spectrum of applications including vaccine development, diagnostics and therapeutic drug applications.

About PharmAust Limited

PharmAust Limited is a unique vertically integrated pharmaceutical business involved in a range of activities from contract drug discovery and development to manufacturing, sales and marketing of healthcare & pharmaceutical products.

PharmAust Limited wholly owns three subsidiary companies:

- PharmAust Manufacturing Pty Ltd
- Epichem Pty Ltd
- Mimotopes Pty Ltd

Further Comment:

Dr John Moursoundis
CEO
PharmAust Limited
P: (+61 8) 9284 8800

Media Enquiries:

Sarah Allchurch
Allchurch Communications
P: (08) 9381 6625
M: 0412 346 412